

News Article downloaded from - <http://www.bioportfolio.com> on Thursday, November 26, 2009
Read [Texan First to Receive CIMZIA\(R\) \(certolizumab pegol\) for Moderately to Severely Active Rheumatoid Arthritis](http://www.bioportfolio.com/news/Texan_First_to_Receive_CIMZIA(R)_certolizumab_pegol_for_Moderately_to_Severely_Active_Rheumatoid_Arthritis) on BioPortfolio.com
([http://www.bioportfolio.com/news/Texan_First_to_Receive_CIMZIA\(R\)_certolizumab.html](http://www.bioportfolio.com/news/Texan_First_to_Receive_CIMZIA(R)_certolizumab.html))

Texan First to Receive CIMZIA(R) (certolizumab pegol) for Moderately to Severely Active Rheumatoid Arthritis

Monday 1st of June 2009 16:15

BioPortfolio no longer holds the full text of this article in PDF form.

[Click Here To Read BioPortfolio's Web Page on Texan First to Receive CIMZIA\(R\) \(certolizumab pegol\) for Moderately to Severely Active Rheumatoid Arthritis](#)

Above results from a Google Custom Search Engine. [Search on BioPortfolio](#)
Via PR Newswire - PRNewswire.co.uk

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472
[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.
BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10
Copyright 1997-2009 - BioPortfolio Limited.

